PengFei Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
PengFei Liu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Shengyu Zhou
Jichenjunchuang Clinical Laboratory, Hangzhou 310022, China
2 shared publications Hao Zhou
Department of Surgery The First Affiliated Hospital of Soochow University Suzhou Jiangsu Province China
1 shared publication- Jiarui Li
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing, China
1 shared publication - Jiaxin Yang
National Clinical Research Center for Obstetric & Gynecologic DiseasesDepartment of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China
1 shared publication - Jingmei Jiang
Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China
1 shared publication - Li Zhou
National Human Diseases Animal Model Resource Center, National Center of Technology Innovation for Animal Model, State Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Science, CAMS & PUMC, Beijing 100021, China
1 shared publication
Latest Publications
- 11 August 2025
- Published by Wiley in Journal of Surgical Oncology
- Vol. 132 (5) , 836-844
Potential of Combination of CE‐MRI and Serum Her‐2neu Extracellular Domain in Evaluating Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer
Background and Objectives: The incidence and mortality rates of breast cancer continue to pose significant challenges. Neoadjuvant chemotherapy is now established as a standardized treatment for locally advanced breast cancer. Notably, a subset of breast cancer patients may attain pathological complete remission (pCR) through neoadjuvant chemotherapy (NAC). The potential to avoid surgery exists if accurate preoperative recognition of complete pathological remission is achieved. Therefore, our research is dedicated to determine the potential of the combination of contrast‐enhanced magnetic resonance imaging (CE‐MRI) method with the serum level of extracellular domain of human epidermal growth factor receptor‐2 (Her‐2neu ECD) in the evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients.Methods: Sixty‐six patients with breast cancer who received NAC in our hospital from September 2019 to July 2022 were enrolled retrospectively, and were divided into the pathological complete remission group and non‐pathological complete remission (n‐pCR) group based on pathological results. All patients underwent 6 to 8 cycles of NAC. Lesions were measured using CE‐MRI and apparent diffusion coefficient (ADC) maps before and after NAC. Serum levels of Her‐2neu ECD were measured by chemiluminescence before and after NAC. The change in tumor volume, maximum diameter and ADC values before and after NAC were calculated. Two logistic prediction model were established based on the independent predictors, and the performance of the models for predicting pCR of NAC were compared.Results: The pCR group and n‐pCR group were included 30 patients (average age, 48 years) and 36 patients (average age, 48 years), respectively. Hormone receptor status (odds ratio [OR], 4.47 [95% CI: 1.40, 14.32]; p = 0.012), human epidermal growth factor receptor‐2 status (OR, 0.15 [95% CI: 0.05, 0.49]; p < 0.01), tumor volume change rate (ΔTV%) during NAC (OR, 1.12 [95% CI: 1.06, 1.26]; p < 0.001), and changes in serum Her‐2neu ECD levels during NAC (OR, 1.14 [95% CI: 1.05, 1.24]; p < 0.001) were independently associated with the odds of achieving pCR. The model that combined ΔTV% and ΔHer‐2neu ECD showed a relatively higher performance (AUC = 0.914, [95%CI: 0.850, 0.978]) than the model included ΔTV% and Her‐2 receptor (AUC = 0.894, [95%CI: 0.819, 0.970]).Conclusion: The model that combined MRI indicators and serum Her‐2neu ECD levels showed a good performance for predicting pCR to NAC in patients with breast cancer.
- 11 August 2025
- Published by Wiley in Journal of Surgical Oncology
- Vol. 132 (5) , 836-844
Potential of Combination of CE‐MRI and Serum Her‐2neu Extracellular Domain in Evaluating Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer
Background and Objectives: The incidence and mortality rates of breast cancer continue to pose significant challenges. Neoadjuvant chemotherapy is now established as a standardized treatment for locally advanced breast cancer. Notably, a subset of breast cancer patients may attain pathological complete remission (pCR) through neoadjuvant chemotherapy (NAC). The potential to avoid surgery exists if accurate preoperative recognition of complete pathological remission is achieved. Therefore, our research is dedicated to determine the potential of the combination of contrast‐enhanced magnetic resonance imaging (CE‐MRI) method with the serum level of extracellular domain of human epidermal growth factor receptor‐2 (Her‐2neu ECD) in the evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients.Methods: Sixty‐six patients with breast cancer who received NAC in our hospital from September 2019 to July 2022 were enrolled retrospectively, and were divided into the pathological complete remission group and non‐pathological complete remission (n‐pCR) group based on pathological results. All patients underwent 6 to 8 cycles of NAC. Lesions were measured using CE‐MRI and apparent diffusion coefficient (ADC) maps before and after NAC. Serum levels of Her‐2neu ECD were measured by chemiluminescence before and after NAC. The change in tumor volume, maximum diameter and ADC values before and after NAC were calculated. Two logistic prediction model were established based on the independent predictors, and the performance of the models for predicting pCR of NAC were compared.Results: The pCR group and n‐pCR group were included 30 patients (average age, 48 years) and 36 patients (average age, 48 years), respectively. Hormone receptor status (odds ratio [OR], 4.47 [95% CI: 1.40, 14.32]; p = 0.012), human epidermal growth factor receptor‐2 status (OR, 0.15 [95% CI: 0.05, 0.49]; p < 0.01), tumor volume change rate (ΔTV%) during NAC (OR, 1.12 [95% CI: 1.06, 1.26]; p < 0.001), and changes in serum Her‐2neu ECD levels during NAC (OR, 1.14 [95% CI: 1.05, 1.24]; p < 0.001) were independently associated with the odds of achieving pCR. The model that combined ΔTV% and ΔHer‐2neu ECD showed a relatively higher performance (AUC = 0.914, [95%CI: 0.850, 0.978]) than the model included ΔTV% and Her‐2 receptor (AUC = 0.894, [95%CI: 0.819, 0.970]).Conclusion: The model that combined MRI indicators and serum Her‐2neu ECD levels showed a good performance for predicting pCR to NAC in patients with breast cancer.
- Open Access
- 12 June 2019
- Published by Wiley in Hematological Oncology
- Vol. 37 (S2) , 415-416
A RETROSPECTIVE ANALYSIS OF REAL‐WORLD OUTCOMES OF CHINESE ELDER PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
- 12 June 2019
- Published by Wiley in Hematological Oncology
- Vol. 37 (S2) , 415-416
Open AccessA RETROSPECTIVE ANALYSIS OF REAL‐WORLD OUTCOMES OF CHINESE ELDER PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
- 1 November 2017
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 12 (11) , S2287
P3.04-007 A Prospective Study of Apatinib in Advanced Small Cell Lung Cancer Patients Failed from Two or More Lines of Chemotherapy
- 1 November 2017
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 12 (11) , S2287
P3.04-007 A Prospective Study of Apatinib in Advanced Small Cell Lung Cancer Patients Failed from Two or More Lines of Chemotherapy